Shamik J. Parikh - Apr 4, 2022 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
Chief Medical Officer
Signature
/s/ Shamik J. Parikh by Dale A. Sander as Attorney-in-Fact
Stock symbol
HUMA
Transactions as of
Apr 4, 2022
Transactions value $
$0
Form type
4
Date filed
4/5/2022, 04:40 PM
Next filing
Dec 12, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HUMA Stock Options (right to buy) Award $0 +145K $0.00 145K Apr 4, 2022 Common Stock 145K $6.90 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The first 25% of the option becomes exercisable on April 4, 2023, after which 1/48 of the option will become exercisable on the 4th of each month through August 4, 2026.